CONSORT diagram. 185 patients treated with tisagenlecleucel were divided into groups based on peak CRS grade experienced: ASTCT grade 3 to 5 CRS (HG-CRS), ASTCT grade 1 to 2 CRS (LG-CRS), and no CRS. The proportion of patients within each CRS group that experienced HLH-LTs is shown. Patients were then grouped into those who experienced CRS and developed HLH-LTs, those with HG-CRS who did not experience HLH-LTs (HG-CRS), and those with no or LG-CRS who did not experience HLH-LTs (NLG-CRS). Shaded boxes indicate inclusion of patients with HLH-LTs. ∗1 patient excluded from survival analyses because of censoring without event at day 17 after CAR T-cell infusion.